Real-world effectiveness of stroke prevention in patients with non-valvular atrial fibrillation treated with rivaroxaban vs. phenprocoumon in Germany - insights from the reload study

被引：0
|
作者：
Bonnemeier, H. [1 ]
Mundhenke, M. [2 ]
Von Mach, T. [2 ]
Huelsebeck, M. [2 ]
机构：
[1] Univ Med Ctr Schleswig Holstein, Dept Electrophysiol & Rhythmol, Kiel, Germany
[2] Bayer Vital GmbH, Leverkusen, Germany
来源：
EUROPEAN HEART JOURNAL | 2017年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P3581
引用
收藏
页码：765 / 765
页数：1
相关论文
共 50 条
  • [41] FACTORS ASSOCIATED WITH BLEEDING EVENTS IN PATIENTS ON RIVAROXABAN FOR NON-VALVULAR ATRIAL FIBRILLATION: A REAL WORLD EXPERIENCE
    Akhtar, Tauseef
    Mattumpuram, Jishanth
    Fugar, Setri
    Ranka, Sagar
    Fratti, Juan Del Cid
    Mann, Hashim
    Uprety, Alok
    Putta, Aakash
    Golzar, Yasmeen
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (09) : 471 - 471
  • [42] Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in "real-world" clinical practice
    Li, Xiaoyan
    Deitelzweig, Steve
    Keshishian, Allison
    Hamilton, Melissa
    Horblyuk, Ruslan
    Gupta, Kiran
    Luo, Xuemei
    Mardekian, Jack
    Friend, Keith
    Nadkarni, Anagha
    Pan, Xianying
    Lip, Gregory Y. H.
    THROMBOSIS AND HAEMOSTASIS, 2017, 117 (06) : 1072 - 1082
  • [43] New Anticoagulants for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation
    Hoecht, T.
    Frick, M.
    Alber, H.
    Huber, K.
    JOURNAL FUR KARDIOLOGIE, 2012, 19 (3-4): : 55 - 62
  • [44] COST-EFFECTIVENESS ANALYSIS OF DABIGATRAN VERSUS RIVAROXABAN FOR NON-VALVULAR ATRIAL FIBRILLATION USING REAL-WORLD EVIDENCE IN MEDICARE BENEFICIARIES
    Peng, S.
    Deger, K.
    Ustyugova, A., V
    Gandhi, P.
    Qiao, N.
    Wang, C.
    Kansal, A.
    VALUE IN HEALTH, 2017, 20 (05) : A269 - A270
  • [45] COST-EFFECTIVENESS OF DABIGATRAN FOR THE PREVENTION OF STROKE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN AUSTRALIA
    Tilden, D.
    Germanos, P.
    Gordon, J.
    Tocchini, L.
    Monz, B.
    VALUE IN HEALTH, 2011, 14 (07) : A375 - A375
  • [46] Patient profile in non-valvular atrial fibrillation (NVAF) and stroke: findings from a real-world setting in Spain
    Lefevre, C.
    Benhaddi, H.
    Lacoin, L.
    Cuervo, H. Diaz
    Lee, Y. -C.
    Evans, D.
    Budd, D.
    EUROPEAN HEART JOURNAL, 2015, 36 : 906 - 906
  • [47] Comparative effcomparative effectiveness and safety of factor-xa inhibitors vs phenprocoumon in patients with non-valvular atrial fibrillation and malignant diseases, insights from the RELOADED study
    Bonnemeier, H.
    Kreutz, R.
    Enders, D.
    Schmedt, N.
    Haeckl, D.
    Vaitsiakhovich, T.
    Kloss, S.
    EUROPEAN HEART JOURNAL, 2019, 40 : 2985 - 2985
  • [48] Cost-effectiveness of rivaroxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation in the Japanese healthcare setting
    Hori, Masatsugu
    Tanahashi, Norio
    Akiyama, Sayako
    Kiyabu, Grace
    Dorey, Julie
    Goto, Rei
    JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (03) : 252 - 261
  • [49] Anticoagulation Therapy in Patients with Non-valvular Atrial Fibrillation in a Private Setting in Brazil: A Real-World Study
    Melo de Barros e Silva, Pedro Gabriel
    Sznejder, Henry
    Vasconcellos, Rafael
    Charles, Georgette M.
    Tannus, Hugo
    Mendonca-Filho, F.
    Mardekian, Jack
    Nascimento, Rodrigo
    Dukacz, Stephen
    Di Fusco, Manuela
    ARQUIVOS BRASILEIROS DE CARDIOLOGIA, 2020, 114 (03) : 457 - 465
  • [50] COMPARATIVE EFFECTIVENESS OF RIVAROXABAN VS VITAMIN K ANTAGONIST IN ROUTINE CARE PATIENTS TREATED FOR NON-VALVULAR ATRIAL FIBRILLATION IN GERMANY - A RENAL IMPAIRMENT SUBGROUP ANALYSIS
    Bonnemeier, H.
    Huelsebeck, M.
    Kloss, S.
    VALUE IN HEALTH, 2017, 20 (09) : A604 - A604
12345